vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $185.2M, roughly 1.1× AMICUS THERAPEUTICS, INC.). On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -6.0%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $2.6M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs -7.4%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
FOLD vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $205.2M |
| Net Profit | $1.7M | — |
| Gross Margin | 85.7% | 16.2% |
| Operating Margin | 8.6% | -14.4% |
| Net Margin | 0.9% | — |
| Revenue YoY | 23.7% | -6.0% |
| Net Profit YoY | -88.5% | — |
| EPS (diluted) | $0.00 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $205.2M | ||
| Q3 25 | $169.1M | $210.3M | ||
| Q2 25 | $154.7M | $228.0M | ||
| Q1 25 | $125.2M | $217.9M | ||
| Q4 24 | $149.7M | $218.2M | ||
| Q3 24 | $141.5M | $213.8M | ||
| Q2 24 | $126.7M | $237.1M | ||
| Q1 24 | $110.4M | $239.2M |
| Q4 25 | $1.7M | — | ||
| Q3 25 | $17.3M | $-9.4M | ||
| Q2 25 | $-24.4M | $-9.4M | ||
| Q1 25 | $-21.7M | $-7.2M | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $-6.7M | $-7.1M | ||
| Q2 24 | $-15.7M | $2.8M | ||
| Q1 24 | $-48.4M | $-6.1M |
| Q4 25 | 85.7% | 16.2% | ||
| Q3 25 | 88.5% | 20.3% | ||
| Q2 25 | 90.2% | 21.5% | ||
| Q1 25 | 90.7% | 21.2% | ||
| Q4 24 | 90.1% | 19.5% | ||
| Q3 24 | 90.6% | 20.8% | ||
| Q2 24 | 91.1% | 22.7% | ||
| Q1 24 | 87.7% | 20.2% |
| Q4 25 | 8.6% | -14.4% | ||
| Q3 25 | 20.3% | -1.6% | ||
| Q2 25 | -6.1% | -1.1% | ||
| Q1 25 | -6.3% | -1.5% | ||
| Q4 24 | 10.7% | -2.0% | ||
| Q3 24 | 15.3% | 0.1% | ||
| Q2 24 | 11.8% | 1.4% | ||
| Q1 24 | -25.1% | 0.1% |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 10.2% | -4.5% | ||
| Q2 25 | -15.8% | -4.1% | ||
| Q1 25 | -17.3% | -3.3% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | -4.8% | -3.3% | ||
| Q2 24 | -12.4% | 1.2% | ||
| Q1 24 | -43.9% | -2.6% |
| Q4 25 | $0.00 | $-2.76 | ||
| Q3 25 | $0.06 | $-0.34 | ||
| Q2 25 | $-0.08 | $-0.34 | ||
| Q1 25 | $-0.07 | $-0.26 | ||
| Q4 24 | $0.05 | $-0.22 | ||
| Q3 24 | $-0.02 | $-0.26 | ||
| Q2 24 | $-0.05 | $0.10 | ||
| Q1 24 | $-0.16 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $66.3M |
| Total DebtLower is stronger | $392.7M | $180.9M |
| Stockholders' EquityBook value | $274.2M | $179.8M |
| Total Assets | $949.9M | $551.2M |
| Debt / EquityLower = less leverage | 1.43× | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $66.3M | ||
| Q3 25 | $263.8M | $54.0M | ||
| Q2 25 | $231.0M | $49.8M | ||
| Q1 25 | $250.6M | $79.1M | ||
| Q4 24 | $249.9M | $71.8M | ||
| Q3 24 | $249.8M | $54.1M | ||
| Q2 24 | $260.1M | $42.1M | ||
| Q1 24 | $239.6M | $48.4M |
| Q4 25 | $392.7M | $180.9M | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | $201.6M | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | $179.8M | ||
| Q3 25 | $230.4M | $251.2M | ||
| Q2 25 | $204.3M | $260.5M | ||
| Q1 25 | $193.6M | $253.1M | ||
| Q4 24 | $194.0M | $245.3M | ||
| Q3 24 | $178.8M | $271.4M | ||
| Q2 24 | $132.5M | $270.5M | ||
| Q1 24 | $130.7M | $277.3M |
| Q4 25 | $949.9M | $551.2M | ||
| Q3 25 | $868.8M | $632.1M | ||
| Q2 25 | $815.3M | $639.4M | ||
| Q1 25 | $789.8M | $657.4M | ||
| Q4 24 | $785.0M | $621.6M | ||
| Q3 24 | $786.6M | $662.5M | ||
| Q2 24 | $749.5M | $666.7M | ||
| Q1 24 | $721.8M | $675.4M |
| Q4 25 | 1.43× | 1.01× | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | 0.82× | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $8.8M |
| Free Cash FlowOCF − Capex | $16.0M | $2.6M |
| FCF MarginFCF / Revenue | 8.6% | 1.3% |
| Capex IntensityCapex / Revenue | 0.2% | 3.0% |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $8.8M | ||
| Q3 25 | $35.7M | $3.6M | ||
| Q2 25 | $-26.5M | $10.7M | ||
| Q1 25 | $7.8M | $10.9M | ||
| Q4 24 | $-3.9M | $19.2M | ||
| Q3 24 | $-23.0M | $10.8M | ||
| Q2 24 | $22.7M | $8.7M | ||
| Q1 24 | $-29.7M | $9.1M |
| Q4 25 | $16.0M | $2.6M | ||
| Q3 25 | $35.3M | $-2.7M | ||
| Q2 25 | $-28.9M | $7.4M | ||
| Q1 25 | $7.5M | $4.8M | ||
| Q4 24 | $-4.2M | $14.0M | ||
| Q3 24 | $-23.3M | $4.6M | ||
| Q2 24 | $21.6M | $1.5M | ||
| Q1 24 | $-31.5M | $3.3M |
| Q4 25 | 8.6% | 1.3% | ||
| Q3 25 | 20.9% | -1.3% | ||
| Q2 25 | -18.7% | 3.3% | ||
| Q1 25 | 6.0% | 2.2% | ||
| Q4 24 | -2.8% | 6.4% | ||
| Q3 24 | -16.5% | 2.2% | ||
| Q2 24 | 17.0% | 0.6% | ||
| Q1 24 | -28.5% | 1.4% |
| Q4 25 | 0.2% | 3.0% | ||
| Q3 25 | 0.2% | 3.0% | ||
| Q2 25 | 1.6% | 1.4% | ||
| Q1 25 | 0.2% | 2.8% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.3% | 2.9% | ||
| Q2 24 | 0.9% | 3.0% | ||
| Q1 24 | 1.6% | 2.4% |
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.11× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
